High Growth Tech Stocks in Australia for October 2024

In This Article:

As the Australian market experiences a flat trading day with the ASX200 closing down slightly at 8,214 points, investors are increasingly turning their attention to sectors like Energy and Health Care, which have shown resilience amid broader economic uncertainties. In this environment of fluctuating market sentiment and renewed concerns about global economic growth, identifying high-growth tech stocks in Australia requires a focus on companies that demonstrate strong fundamentals and adaptability to changing conditions.

Top 10 High Growth Tech Companies In Australia

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.32%

27.42%

★★★★★★

Adherium

86.80%

73.66%

★★★★★★

ImExHS

20.47%

111.20%

★★★★★★

Telix Pharmaceuticals

20.10%

38.31%

★★★★★★

DUG Technology

10.79%

31.83%

★★★★★☆

AVA Risk Group

32.56%

118.83%

★★★★★★

Careteq

37.17%

126.21%

★★★★★☆

Pointerra

56.62%

126.45%

★★★★★★

Wrkr

36.31%

100.29%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Click here to see the full list of 64 stocks from our ASX High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Pro Medicus

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$19.46 billion.

Operations: Pro Medicus generates revenue primarily through the production of integrated software applications for the healthcare industry, amounting to A$161.50 million. The company focuses on providing advanced imaging and radiology information system software services to a diverse clientele in multiple regions, including Australia, North America, and Europe.

Pro Medicus, a trailblazer in healthcare imaging software, has demonstrated robust financial health and growth prospects. In the fiscal year ending June 2024, the company reported a significant revenue jump to AUD 166.33 million from AUD 127.33 million previously, underscoring an impressive growth trajectory with earnings surging by 36.5% over the past year—outpacing the industry average of 15.4%. This performance is bolstered by strategic R&D investments which have consistently aligned with revenue growth; last year alone, R&D expenses were notably high as a percentage of revenue, ensuring continuous innovation and enhancement of their offerings. Looking ahead, Pro Medicus appears well-positioned for sustained growth with projected annual earnings increases of 18.9%, surpassing broader Australian market expectations (12.2%). The company also raised its dividend payout to shareholders significantly by 33%, reflecting confidence in ongoing profitability and cash flow positivity—an attractive indicator for potential investors seeking companies with forward-thinking management and solid financial foundations in the dynamic tech landscape.